Cancer represents a major clinical challenge, also due to its substantial burden of vascular complications. Cancer-associated vascular occlusions, including ischaemic stroke, arise from the combined influence of diverse clinical and biological drivers. The intensity and relative contribution of these mechanisms vary across tumour types and disease stages and can ultimately shape clot composition. In this narrative review, we summarize the principal clinical and biological determinants that promote vascular occlusions in cancer, examine the available literature on the cellular and molecular composition of cancer-associated clots in stroke, and highlight gaps and emerging directions in clot composition studies. Histopathological studies indicate that cerebral arterial clots retrieved from patients with active cancer tend to exhibit a platelet- and fibrin-enriched architecture, with a relative reduction in erythrocyte content compared with non-cancer stroke controls. Importantly, a growing body of case reports and small series has demonstrated that tumour cells or tumour fragments can be identified within retrieved cerebral arterial clots of cancer patients with stroke. Conversely, inflammatory signatures within cancer-related thrombi remain less characterized. A better understanding of clot composition in cancer patients might have important implications for refining the understanding of cancer-associated vascular events and guiding future diagnostic and treatment strategies.
PrandoniPFalangaAPiccioliA.Cancer and venous thromboembolism. Lancet Oncol2005; 6(6): 401–410.
3.
KhoranaAAFrancisCWCulakovaE, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost2007; 5(3): 632–634.
NaviBBReinerASKamelH, et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol2017; 70(8): 926–938.
6.
NewtonHB.Neurologic complications of systemic cancer. Am Fam Physician1999; 59(4): 878–886.
7.
ArboixA.[Cerebrovascular disease in the cancer patient]. Rev Neurol2000; 31(12): 1250–1252.
8.
NaviBBIadecolaC.Ischemic stroke in cancer patients: a review of an underappreciated pathology. Ann Neurol2018; 83(5): 873–883.
9.
MelloSJudgeCKellyR, et al. A systematic review of the causes and management of nonthrombotic embolic stroke of tissue origin. Stroke Res Treat2018; 2018: 8092862.
10.
BeyelerMBirnerBBrancaM, et al. Development of a score for prediction of occult malignancy in stroke patients (OCCULT-5 score). J Stroke Cerebrovasc Dis2022; 31(8): 106609.
11.
BalanescuDVBloomingdaleRDonisanT, et al. Mechanisms of myocardial ischemia in cancer patients: a state-of-the-art review of obstructive versus non-obstructive causes. Rev Cardiovasc Med2022; 23(7): 227.
12.
Sabate-TormosMBardajiAPeiroOM, et al. Cancer and myocardial injury in patients with suspected acute coronary syndrome. Cardiooncology2025; 11(1): 21.
13.
NewcomerKBifolcoAReevesS, et al. Macrovascular tumor infiltration and circulating tumor cell cluster dynamics in patients with cancer approaching the end of life. Nat Med2025; 31(12): 4140–4149.
14.
KhoranaAAFrancisCWCulakovaE, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer2007; 110(10): 2339–2346.
15.
CarrierMLe GalGChoR, et al. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost2009; 7(5): 760–765.
16.
GonYSakaguchiMYamagamiH, et al. Predictors of survival in patients with ischemic stroke and active cancer: a prospective, multicenter, observational study. J Am Heart Assoc2023; 12(15): e029618.
17.
NaviBBHowardGHowardVJ, et al. New diagnosis of cancer and the risk of subsequent cerebrovascular events. Neurology2018; 90(23): e2025–e2033.
18.
AyCDunklerDMarosiC, et al. Prediction of venous thromboembolism in cancer patients. Blood2010; 116(24): 5377–5382.
19.
FalangaAMarchettiMVignoliA.Coagulation and cancer: biological and clinical aspects. J Thromb Haemost2013; 11(2): 223–233.
20.
RiouxBWhiteleyW.Hard times for anticoagulation in cancer-associated stroke. Neurology2025; 105(10): e214395.
21.
KhanFTritschlerTMarxCE, et al. Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis. Eur Heart J2025; 2025: ehaf453.
22.
LymanGHCarrierMAyC, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv2021; 5(4): 927–974.
23.
FalangaAMarchettiMRussoL.The mechanisms of cancer-associated thrombosis. Thromb Res2015; 135(suppl 1): S8–S11.
24.
BangOYChungJWLeeMJ, et al. Cancer cell-derived extracellular vesicles are associated with coagulopathy causing ischemic stroke via tissue factor-independent way: the OASIS-CANCER study. PLoS One2016; 11(7): e0159170.
25.
JoJTSchiffDPerryJR.Thrombosis in brain tumors. Semin Thromb Hemost2014; 40(3): 325–331.
26.
ElbardissiAWDearaniJADalyRC, et al. Embolic potential of cardiac tumors and outcome after resection: a case–control study. Stroke2009; 40(1): 156–162.
27.
FalangaARussoLVerzeroliC.Mechanisms of thrombosis in cancer. Thromb Res2013; 131(suppl 1): S59–S62.
28.
KhoranaAAMcCraeKR.Risk stratification strategies for cancer-associated thrombosis: an update. Thromb Res2014; 133(suppl 2): S35–S38.
29.
DardiotisEAloizouAMMarkoulaS, et al. Cancer-associated stroke: pathophysiology, detection and management (review). Int J Oncol2019; 54(3): 779–796.
30.
FalangaARussoLMilesiV, et al. Mechanisms and risk factors of thrombosis in cancer. Crit Rev Oncol Hematol2017; 118: 79–83.
31.
ZhaoHWuLYanG, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther2021; 6(1): 263.
32.
BangOYChungJWLeeMJ, et al. Cancer-related stroke: an emerging subtype of ischemic stroke with unique pathomechanisms. J Stroke2020; 22(1): 1–10.
33.
NaviBBShermanCPGenovaR, et al. Mechanisms of ischemic stroke in patients with cancer: a prospective study. Ann Neurol2021; 90(1): 159–169.
von BruhlMLStarkKSteinhartA, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med2012; 209(4): 819–835.
36.
BarbuiTFinazziGFalangaA.The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood1998; 91(9): 3093–3102.
37.
HeoJHYunJKimKH, et al. Cancer-associated stroke: thrombosis mechanism, diagnosis, outcome, and therapeutic strategies. J Stroke2024; 26(2): 164–178.
38.
StrasenburgWJozwickiJDurslewiczJ, et al. Tumor cell-induced platelet aggregation as an emerging therapeutic target for cancer therapy. Front Oncol2022; 12: 909767.
39.
LucottiSOgitaniYKenificCM, et al. Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin beta 2. Cell2025; 188(6): 1642–1661.e24.
40.
CostamagnaGHottingerAMilionisH, et al. Clinical and demographic characteristics, mechanisms, and outcomes in patients with acute ischemic stroke and newly diagnosed or known active cancer. Neurology2023; 100(24): e2477–e2489.
41.
Mahringer-KunzAMeyerFIHahnF, et al. Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma: prevalence and clinical significance. United European Gastroenterol J2021; 9(5): 590–597.
HussainSMA. Tumor embolism and acute arterial occlusion: a systematic review. Surg Open Sci2022; 10: 216–222.
45.
MiroslavMLazarDAleksandarM, et al. Rare forms of peripheral arterial embolism: review of 11 cases. Vascular2005; 13(4): 222–229.
46.
GiTKuwaharaAYamashitaA, et al. Histopathological features of cancer-associated venous thromboembolism: presence of intrathrombus cancer cells and prothrombotic factors. Arterioscler Thromb Vasc Biol2023; 43(1): 146–159.
47.
OhshimaKTsujiiYSakaiK, et al. Massive tumor embolism in the abdominal aorta from pulmonary squamous cell carcinoma: case report and review of the literature. Pathol Int2017; 67(9): 467–471.
48.
TorunoMAl-JanabiOKaramanI, et al. Mechanical thrombectomy for the treatment of large vessel occlusion due to cancer-related cerebral embolism: a systematic review. Interv Neuroradiol2024; 2024: 15910199241230356.
49.
FujiwaraYHayashiKShibataY, et al. Cerebral tumor embolism from thyroid cancer treated by mechanical thrombectomy: illustrative case. J Neurosurg Case Lessons2023; 5(5): CASE22293.
50.
WolpertFKulcsarZHanselM, et al. Embolization of tumor cells is rare in patients with systemic cancer and cerebral large vessel occlusion. Eur J Neurol2020; 27(10): 2041–2046.
51.
OyamaTAsaiTMiyazawaT, et al. A case of cerebral tumor embolism from extracardiac lung cancer treated by mechanical thrombectomy. NMC Case Rep J2020; 7(3): 101–105.
52.
MoriyamaTSugiuraYHayashiY, et al. Mechanical thrombectomy for acute middle cerebral artery occlusion caused by tumor embolism: a case report. J Neuroendovasc Ther2021; 15(1): 52–57.
53.
PopRMihocDManisorM, et al. Mechanical thrombectomy for repeated cerebral tumor embolism from a thoracic sarcomatoid carcinoma. J Neurointerv Surg2018; 10(10): e26.
54.
UsuiGTakayamaYHashimotoH, et al. Cerebral embolism caused by thrombus in the pulmonary vein stump after left lower lobectomy: a case report and literature review. Intern Med2019; 58(9): 1349–1354.
55.
HughesSEHunterACampbellJ, et al. Extraction of tumour embolus following perioperative stroke. J Neurol Sci2015; 353(1–2): 172–174.
56.
ChenPQingQDiaoM, et al. Surgical procedure of segmentectomy as a possible cause of postoperative cerebral embolism: a case report. J Cardiothorac Surg2020; 15(1): 334.
57.
GoddardJKNussbaumESMadisonM, et al. Endovascular aspiration to treat acute ischemic stroke caused by embolic carcinoma. Interv Neuroradiol2019; 25(4): 403–406.
58.
YoshikawaSKamideTKasakuraS, et al. A case of cerebral infarction due to pleomorphic carcinoma of the lung. Surg Neurol Int2020; 11: 217.
59.
NakanishiKKawanoHYamagishiY, et al. Tumor cells detected in retrieved thrombus: cancer-associated stroke. Intern Med2021; 60(15): 2491–2494.
60.
TanakaSItoYYoshimotoT, et al. Cancer-related cerebral embolism caused by metastatic cardiac tumour from renal cell carcinoma. BMJ Case Rep2025; 18(4): e265532.
61.
SemeranoASaliouGSanvitoF, et al. Fishing an anemone in the brain: embolized cardiac fibroelastoma revealed after stroke thrombectomy. Eur Heart J2021; 42(39): 4094–4095.
62.
SalamKARafeequeMHashimH, et al. Histology of thrombectomy specimen reveals cardiac tumor embolus in cryptogenic young stroke. J Stroke Cerebrovasc Dis2018; 27(4): e70–e72.
63.
IzumiKTakeuchiYIwabuchiN, et al. Mechanical thrombectomy for cerebral embolism due to cardiac papillary fibroelastoma: a case report. Surg Neurol Int2025; 16: 141.
64.
BiraschiFDianaFAlesiniF, et al. Effective ADAPT thrombectomy in a patient with acute stroke due to cardiac papillary elastofibroma: histological thrombus confirmation. J Stroke Cerebrovasc Dis2016; 25(10): e185–e187.
65.
TejadaJGalianaABalboaO, et al. Mechanical endovascular procedure for the treatment of acute ischemic stroke caused by total detachment of a papillary fibroelastoma. J Neurointerv Surg2014; 6(6): e37.
66.
LiSBesantGMuccilliA, et al. Histopathological findings of endovascular thrombectomy-retrieved specimen reveal cardiac papillary fibroelastoma as the cause of ischaemic stroke. BMJ Case Rep2025; 18(3): 132.
67.
SantosAFPinhoJRamosV, et al. Stroke and cardiac papillary fibroelastoma: mechanical thrombectomy after thrombolytic therapy. J Stroke Cerebrovasc Dis2014; 23(5): 1262–1264.
68.
ItratAGeorgePKhawajaZ, et al. Pathological evidence of cardiac papillary fibroelastoma in a retrieved intracranial embolus. Can J Neurol Sci2015; 42(1): 66–68.
69.
ZhangJGuanXZhangG, et al. Two cerebral infarctions caused by thrombus and myxomatous embolus in a patient with cardiac myxoma: a case report. Heliyon2024; 10(9): e30199.
70.
LazovicLBosnjakovicPAbouseduYAI, et al. Mechanical thrombectomy for acute ischemic stroke with simultaneous aorto-iliac occlusion due to cardiac myxoma dislodgement – case report with review of the literature. Ideggyogy Sz2025; 78(5–6): 199–206.
71.
VantyghemSStaessensSFrancoisO, et al. Mechanical thrombectomy for acute ischemic stroke revealing a cardiac myxoma: histological and immunohistochemical study to determine myxomatous emboli. Acta Neurol Belg2023; 123(3): 1201–1203.
72.
RyuBIshikawaTSatoS, et al. Mechanical endovascular recanalization in a patient with middle cerebral artery occlusion by tumorous emboli originating from cardiac myxoma. NMC Case Rep J2015; 2(2): 53–56.
73.
Garcia-PtacekSMatias-GuiuJAValencia-SanchezC, et al. Mechanical endovascular treatment of acute stroke due to cardiac myxoma. J Neurointerv Surg2014; 6(1): e1.
74.
BaekSHParkSLeeNJ, et al. Effective mechanical thrombectomy in a patient with hyperacute ischemic stroke associated with cardiac myxoma. J Stroke Cerebrovasc Dis2014; 23(9): e417–e419.
75.
UnedaASuzukiKHirashitaK, et al. Tandem cervical/intracranial internal carotid artery occlusion due to cardiac myxoma treated successfully with mechanical endovascular thrombectomy. Acta Neurochir2016; 158(7): 1393–1395.
76.
ByonJHKwakHSChungGH, et al. Acute stroke from tumor embolus in a patient with cardiac sarcoma: aspiration thrombectomy with Penumbra catheter. Interv Neuroradiol2016; 22(1): 88–90.
77.
ArakiSMaekawaKKobayashiK, et al. Tumor embolism through right-to-left shunt due to venous invasion of esophageal carcinoma. J Stroke Cerebrovasc Dis2020; 29(12): 105352.
78.
MatsunagaKKikunoMSakamotoH, et al. A cerebral embolism caused by a malignant peripheral nerve sheath tumor in a patient with neurofibromatosis type 1. Intern Med2024; 63(22): 3087–3091.
79.
NishiAGotoYYamanakaK, et al. A direct aspiration first pass technique for basilar artery occlusion caused by elastic-hard tumor embolus via the pulmonary vein by metastatic prostate adenocarcinoma: a case report. NMC Case Rep J2021; 8(1): 95–100.
80.
KimCSJungHRChoKH, et al. Forced-suction thrombectomy of an arterial tumor embolism due to metastatic melanoma. Arch Neurol2012; 69(2): 272–273.
81.
NukataRIkedaHAkaikeN, et al. White embolus-induced basilar artery occlusion due to pulmonary vein invasion of a metastasis of a malignant melanoma. Intern Med2023; 62(19): 2889–2893.
82.
BhatiaSKuAPuC, et al. Endovascular mechanical retrieval of a terminal internal carotid artery breast tumor embolus. J Neurosurg2010; 112(3): 572–574.
83.
FukamiYYamaguchiKMiyasakiA, et al. Acute ischemic stroke due to undifferentiated sarcoma: a case report and literature review. Intern Med2019; 58(1): 115–118.
84.
BacigaluppiMSemeranoAGullottaGS, et al. Insights from thrombi retrieved in stroke due to large vessel occlusion. J Cereb Blood Flow Metab2019; 39(8): 1433–1451.
85.
FuCHChenCHLinYH, et al. High fibrin and platelet clot predicts stroke recurrence or mortality after thrombectomy in patients with active cancer. J Neurointerv Surg2025; 17(11): 1189–1194.
86.
ParkHKimJHaJ, et al. Histological features of intracranial thrombi in stroke patients with cancer. Ann Neurol2019; 86(1): 143–149.
87.
MatsumotoNFukudaHHandaA, et al. Histological examination of Trousseau syndrome-related thrombus retrieved through acute endovascular thrombectomy: report of 2 cases. J Stroke Cerebrovasc Dis2016; 25(12): e227–e230.
88.
WoockMRossiRJabrahD, et al. Clot signature in patients with large vessel occlusion stroke and concomitant active cancer. Eur J Neurol2025; 32(1): e70037.
89.
FuCHChenCHLinYH, et al. Fibrin and platelet-rich composition in retrieved thrombi hallmarks stroke with active cancer. Stroke2020; 51(12): 3723–3727.
90.
KataokaYSonodaKTakahashiJC, et al. Histopathological analysis of retrieved thrombi from patients with acute ischemic stroke with malignant tumors. J Neurointerv Surg2022; 14(5): neurintsurg-2020-017195.
91.
YooJKwonIKimS, et al. Coagulation factor expression and composition of arterial thrombi in cancer-associated stroke. Stroke2023; 54(12): 2981–2989.
92.
HeoJLeeHSeogY, et al. Cancer prediction with machine learning of thrombi from thrombectomy in stroke: multicenter development and validation. Stroke2023; 54(8): 2105–2113.
93.
MagamiSYoshidaKNakaoY, et al. A single-center experience of mechanical thrombectomy for cancer-associated ischemic stroke. J Neuroendovasc Ther2024; 18(2): 37–46.
94.
SunYENaHKKwakS, et al. Different thrombus histology in a cancer patient with deep vein thrombosis and recurrent strokes. J Stroke2022; 24(2): 300–302.
95.
YamashitaAGiTSatoY.Histological differences among thrombi in thrombotic diseases. Curr Opin Hematol2025; 32(3): 146–156.
96.
IkedaHIshibashiRKinosadaM, et al. Factors related to white thrombi in acute ischemic stroke in cancer patients. Neuroradiol J2023; 36(4): 453–459.
97.
Lopez-PedreraCOterosRIbanez-CostaA, et al. The thrombus proteome in stroke reveals a key role of the innate immune system and new insights associated with its etiology, severity, and prognosis. J Thromb Haemost2023; 21(10): 2894–2907.
98.
PekayvazKKilaniBJoppichM, et al. Immunothrombolytic monocyte–neutrophil axes dominate the single-cell landscape of human thrombosis and correlate with thrombus resolution. Immunity2025; 58(5): 1343–1358.e13.
99.
WahabRHasanMMAzamZ, et al. The role of coagulome in the tumor immune microenvironment. Adv Drug Deliv Rev2023; 200: 115027.
100.
NaviBBZhangCMillerB, et al. Apixaban vs aspirin in patients with cancer and cryptogenic stroke: a post hoc analysis of the ARCADIA randomized clinical trial. JAMA Neurol2024; 81(9): 958–965.
101.
NaviBBMarshallRSBobrowD, et al. Enoxaparin vs aspirin in patients with cancer and ischemic stroke: the TEACH pilot randomized clinical trial. JAMA Neurol2018; 75(3): 379–381.
102.
Martinez-MajanderNNtaiosGLiuYY, et al. Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial. Eur J Neurol2020; 27(5): 841–848.
103.
ChungJWHwangJKimHJ, et al. Edoxaban for the treatment of hypercoagulability and cerebral thromboembolism associated with cancer: a randomized clinical trial of biomarker targets. Int J Stroke2024; 19(6): 645–653.
104.
JangHLeeJJLeeMJ, et al. Comparison of enoxaparin and warfarin for secondary prevention of cancer-associated stroke. J Oncol2015; 2015: 502089.
105.
NamKWKimCKKimTJ, et al. Treatment of cryptogenic stroke with active cancer with a new oral anticoagulant. J Stroke Cerebrovasc Dis2017; 26(12): 2976–2980.
106.
NaitoHNezuTHosomiN, et al. Antithrombotic therapy strategy for cancer-associated ischemic stroke: a case series of 26 patients. J Stroke Cerebrovasc Dis2018; 27(9): e206–e211.
107.
LaubeESYuAGuptaD, et al. Rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation and active cancer. Am J Cardiol2017; 120(2): 213–217.
108.
MaheICarrierMMayeurD, et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism. N Engl J Med2025; 392(14): 1363–1373.
109.
CaineGJStonelakePSLipGY, et al. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia2002; 4(6): 465–473.
110.
GenchiASemeranoASchwarzG, et al. Neutrophils predominate the immune signature of cerebral thrombi in COVID-19 stroke patients. Acta Neuropathol Commun2022; 10(1): 14.
111.
DaiCSMishraAEddJ, et al. Circulating tumor cells: blood-based detection, molecular biology, and clinical applications. Cancer Cell2025; 43(8): 1399–1422.
112.
PatellRZwickerJISinghR, et al. Machine learning in cancer-associated thrombosis: hype or hope in untangling the clot. Bleeding Thromb Vasc Biol2024; 3(suppl 1): 123.
113.
TurizoMJFPatellRZwickerJI.Identifying novel biomarkers using proteomics to predict cancer-associated thrombosis. Bleeding Thromb Vasc Biol2024; 3(suppl 1): 120.
114.
WenzlFAOwKWVeldersMA, et al. Prediction of mortality, bleeding, and ischaemic events in patients with cancer and acute coronary syndrome: a model development and validation study. Lancet2026; 407(10527): 515–528.
